secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001564590-21-056507
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q3 net loss $24.6M; cash $385M; acquired ScalmiBio
---------------------------------------------------------------

- GAAP net loss $24.6M ($0.61/sh) vs $10.8M ($0.36/sh) in Q3 2020; non-GAAP loss $20.4M.
- R&D expenses $18.2M, up from $5.3M, driven by higher clinical costs and stock-based comp.
- Cash and equivalents $385.1M; runway projected through 2024.
- Acquired ScalmiBio Oct 2021 for ~$4.5M upfront + $2M milestone and royalties; gains SHIELD ADC platform.
- Dosed first patients in ASPEN-05 (AML) and Zymeworks combo trial; ASH/SITC data presented or pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000156459021056507/0001564590-21-056507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000156459021056507/alxo-8k_20211111.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-056507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer